|Funding for:||UK Students, EU Students, International Students|
|Hours:||Full Time, Part Time|
|Placed On:||24th April 2019|
|Closes:||21st June 2019|
Health technology assessment (HTA) is a multidisciplinary process to systematically evaluate the clinical, economic and broader impact of the use of a health technology. Evidence on clinical effectiveness can arise from multiple sources. In a hierarchy of study designs, randomised controlled trials are often considered to be the gold standard for evaluating a technology. Regulatory agencies may grant marketing authorisation on the basis of evidence from single-arm studies because it is unethical to randomise patients or difficult to recruit. Such lack of comparative evidence complicates economic evaluations used to assess which of several treatments should be adopted by a health care system. The need for indirect comparison methodology to assess relative treatment effects has led to the development of novel statistical methods and raised methodological challenges.
This research aims to explore methods for adjusting for biases and characterise uncertainty arising from the use of single-arm studies in economic models.
This PhD is jointly funded by GSK and the University of Sheffield. In addition to the supervisors from the University of Sheffield, staff from GSK will also be part of the supervisory team. You will be given the opportunity to spend time at GSK to gain work and research experience.
- Honours Bachelor degree (2.1 or above) in Mathematics or Statistics
- Master’s degree at Merit in Statistics or subject with high statistical content, OR equivalent experience
How to Apply:
Please complete a University Postgraduate Research Application form available here: https://www.sheffield.ac.uk/postgradapplication/
Please clearly state the title of the studentship, the prospective main supervisor (Dr John W Stevens) and select ScHARR as the department.
Please also include:
- a covering letter explaining why you wish to apply for this studentship
- a copy of your CV
Funding is provided by GlaxoSmithKline plc (GSK) and the University of Sheffield. It is proposed that the project should start in October 2019.
Applications are open to UK, EU and Overseas candidates.
Applicants can choose between part time or full time study (dependent on visa regulations for Overseas candidates). Funding covers full tuition fees (Home, EU or Overseas) and a quarterly stipend at the UKRI rate (currently £15,009 for the 2019/20 academic year). There is also a £750 per annum support grant to assist with research costs.
Type / Role: